What is the standard of care for metastatic Bladder Cancer according to NCCN guidelines

Standard of Care for Metastatic Bladder Cancer (NCCN Guidelines)

Based on the NCCN Guidelines Version 2.2025, here's what you need to know about how metastatic bladder cancer is typically managed:

Initial Evaluation

When metastatic bladder cancer is diagnosed, your care team will first assess the extent of disease through:

• Chest CT scan to check for lung involvement
• Bone imaging (bone scan or MRI) if there are signs of skeletal involvement
• CNS imaging (brain/spinal cord imaging) to be considered
• Kidney function testing (GFR) to determine if you're eligible for certain chemotherapy drugs like cisplatin
• Molecular/genomic testing - This is now recommended early at diagnosis of advanced disease. Testing should look for:
  • FGFR3 genetic alterations (which may make you eligible for the targeted drug erdafitinib)
  • HER2 overexpression (which may make you eligible for fam-trastuzumab deruxtecan)
  • PD-L1 status (which helps determine checkpoint inhibitor eligibility)

According to NCCN Guidelines, approximately 93% of advanced urothelial carcinoma cases have at least one clinically relevant genetic alteration, so this testing is important for identifying your treatment options.

First-Line Systemic Therapy (Primary Treatment)

For patients with metastatic disease, systemic therapy (chemotherapy and/or immunotherapy) is the standard approach. The specific treatment depends on:

1. Your kidney function (can you tolerate cisplatin?)
2. Your molecular/genetic test results (FGFR3, HER2, PD-L1 status)
3. Your overall health and performance status

Treatment Options Generally Include:

For cisplatin-eligible patients:

• Platinum-based chemotherapy (typically cisplatin combined with gemcitabine) is a standard first-line option
• Checkpoint inhibitors (immunotherapy drugs) may be combined with chemotherapy

For cisplatin-ineligible patients:

• Checkpoint inhibitor monotherapy (like atezolizumab) based on PD-L1 testing
• Alternative chemotherapy regimens

Targeted therapies (based on molecular testing):

• Erdafitinib for FGFR3-altered tumors
• Fam-trastuzumab deruxtecan for HER2-overexpressing tumors

Oligometastatic Disease (Limited Spread)

For highly selected patients with oligometastatic disease (only a few sites of spread) who respond well to initial systemic therapy, NCCN Guidelines note that metastasectomy (surgical removal of metastases) may be considered. However, this requires:

• Careful patient selection
• Good response to systemic therapy beforehand
• Solitary or limited metastatic lesions
• Favorable performance status and overall health
• Typically lung or lymph node sites of disease

The NCCN panel emphasizes that metastasectomy should only be pursued in select cases because evidence is limited and the surgery can be extensive.

Second-Line and Beyond

If your cancer progresses on first-line treatment, additional systemic therapy options exist, including other checkpoint inhibitors, targeted therapies, and chemotherapy combinations—but these are individualized based on your specific situation.

Key Questions to Ask Your Oncology Team

1. What are my molecular/genetic test results, and what treatment options do they open up for me?
2. Am I eligible for cisplatin-based chemotherapy, or do I need alternative options?
3. What is the recommended first-line treatment for my specific situation, and why?
4. What are the expected benefits and side effects of the recommended treatment?
5. Are there clinical trials available that might be appropriate for me?
6. If my cancer progresses on first-line treatment, what second-line options would be available?

---

Important Context

According to NCCN Guidelines, approximately 5% of bladder cancer patients have metastatic disease at diagnosis, and about half of all patients relapse after surgery depending on their initial stage. This means metastatic bladder cancer is a serious diagnosis, but modern treatment approaches—particularly the newer targeted therapies and immunotherapies—have expanded options significantly compared to previous years.

The NCCN panel notes that "immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies have emerged as new options for the treatment of metastatic bladder cancer," and experts expect treatment outcomes to continue improving.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.